[go: up one dir, main page]

WO1998001131A1 - Medicaments induisant une action ultrasonore et appareil d'utilisation de ces medicaments - Google Patents

Medicaments induisant une action ultrasonore et appareil d'utilisation de ces medicaments Download PDF

Info

Publication number
WO1998001131A1
WO1998001131A1 PCT/JP1997/002285 JP9702285W WO9801131A1 WO 1998001131 A1 WO1998001131 A1 WO 1998001131A1 JP 9702285 W JP9702285 W JP 9702285W WO 9801131 A1 WO9801131 A1 WO 9801131A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
xanthene dye
ultrasonic
derivative
xanthene
Prior art date
Application number
PCT/JP1997/002285
Other languages
English (en)
Japanese (ja)
Inventor
Kenichi Kawabata
Shinichiro Umemura
Kazuaki Sasaki
Nami Sugita
Original Assignee
Hitachi, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hitachi, Ltd. filed Critical Hitachi, Ltd.
Publication of WO1998001131A1 publication Critical patent/WO1998001131A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • C07D311/82—Xanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/22—Implements for squeezing-off ulcers or the like on inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; for invasive removal or destruction of calculus using mechanical vibrations; for removing obstructions in blood vessels, not otherwise provided for
    • A61B17/22004—Implements for squeezing-off ulcers or the like on inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; for invasive removal or destruction of calculus using mechanical vibrations; for removing obstructions in blood vessels, not otherwise provided for using mechanical vibrations, e.g. ultrasonic shock waves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N7/00—Ultrasound therapy

Definitions

  • the present invention relates to a method for treating acoustic or cavitation using acoustic cavitation, a chemical reaction by ultrasonic waves, generation of bubbles by ultrasonic waves, ultrasonic imaging using bubbles, or sterilization of a liquid.
  • the present invention relates to an agent for inducing an ultrasonic action, which contains a compound having an action for reducing the effect of an ultrasonic wave, and an ultrasonic apparatus using the same.
  • Techniques for treating tumors, calculi, etc. by irradiating focused ultrasound from outside the body are less invasive than open surgery, lowering physical strength during surgery and quality of life after surgery (Quality of Life). ) Is excellent in principle, and is considered to increase social value in the future.
  • Acoustic cavitation is considered to play an important role in the mechanism by which the therapeutic effect can be obtained by the irradiation of convergent ultrasonic waves, and in the mechanism of promoting the chemical reaction by the irradiation of ultrasonic waves.
  • acoustic cavitation occurs in the living body and bubbles It is described that when generated, the generated bubbles can produce an ultrasound contrast effect.
  • JP Hei 2 The technology described in JP-A-26848 focuses on the fact that the ultrasonic irradiation time required to generate acoustic cavitation is 1 msec to 100 msec, and two types of sound fields with different ultrasonic wavefronts are used.
  • the sound field is switched by repeating the cycle of irradiating ultrasonic waves while switching at time intervals of 1 msec to 100 msec, and crushing the hairpin cavitation generated by one sound field by the other sound field.
  • the efficiency of sonochemical action is improved by an order of magnitude at the same ultrasonic power compared to the case without.
  • Ultrasonics Sonoch em istryvo 1.3, No. 1, pp. 1-6 (1996) (Kawa bata, K and Umemu ra, S) usually obtains only when there is a reflective object.
  • the technique of the second harmonic superposition method which obtains an ultrasonic wave having a waveform that is advantageous for generating acoustic cavitation even in a situation where there is no reflector, describes an ultrasonic wave that is advantageous for generating acoustic cavitation.
  • a substance such as porphyrin is used as a substance that generates active oxygen by the chemical action of ultrasound.
  • a substance such as porphyrin has a force that has a function of generating active oxygen secondary by acoustic cavitation generated by ultrasonic waves, and a threshold value for generating acoustic cavitation. Can not cause a decline in
  • acoustic cavitation threshold the threshold of the sound intensity at which acoustic cavitation is generated by a chemical method
  • an ultrasonic action-inducing (or attraction) technique which makes it possible to generate acoustic cavitation with lower acoustic intensity, which was not possible with the prior art approach.
  • short-lived chemical species such as hydroxyl radicals generated by acoustic cavitation, and secondary generated chemical species caused by these short-lived chemical species.
  • An object of the present invention is to provide an ultrasonic action inducer that does not suppress (prevent) the chemical action of short-lived chemical species in order to perform a chemical treatment based on the drug, and to provide an ultrasonic apparatus using the drug.
  • the ultrasonic action inducer of the present invention comprises a compound comprising a xanthene dye containing a xanthene ring or a derivative of a xanthene dye, and is an agent for lowering the threshold of acoustic intensity for generating acoustic cavitation.
  • a halogenated acetate amide group containing a xanthene ring or a derivative of a xanthene dye
  • the ultrasonic action inducer of the present invention comprises a compound comprising a xanthene dye containing a xanthene ring or a derivative of a xanthene dye, and is an agent for lowering the threshold of acoustic intensity for generating acoustic cavitation.
  • R 2 shown in Fig. 4 is any functional group of a halogenated acetamido group, maleimide group, aziridine group, isothiocyanate group, succinimid group, and sulfonyl chloride group.
  • the above derivative has the structure of ONa and COONa in which H of OH and COOH is replaced by Na in FIG. 4, and may be a salt of a xanthene dye.
  • a substance in which two molecules of a xanthene dye or a derivative of a xanthene dye containing a xanthene ring are linked by — (CH 2 ) favour-(3 ⁇ n (integer) (hereinafter, a xanthene dye or a derivative of a xanthene dye derivative) Dimer), and the threshold of the sound intensity to generate acoustic cavitation.
  • the above derivative has two or more halogens bonded to the carbon atom of the skeleton of the xanthene dye.
  • the derivative has a halogenated acetoamide group bonded to the carbon atom of the skeleton of the xanthene dye.
  • R 2 shown in FIG. 10 is any one of a halogenated acetoamide group, a maleimide group, an aziridine group, an isothiocyanate group, a succinimid group, and a sulfonyl chloride group.
  • the above derivative has a structure of ONa in which H of OH is replaced by Na in FIG. 10, and may be a salt of a xanthene dye or a dimer of a derivative of the xanthene dye.
  • An ultrasonic apparatus using the ultrasonic wave inducer of the present invention includes a compound (including a dimer) of a xanthene dye containing a xanthene ring or a derivative of a xanthene dye, and has a threshold of an acoustic intensity for generating an acoustic cavitation.
  • a means for administering the ultrasonic action inducer to be reduced to a target site of the subject; and a means for superimposing ultrasonic waves having a plurality of center frequencies having an acoustic intensity of 1 O WZ cm 2 or less and irradiating the target site. And means for detecting ultrasonic waves from a target site.
  • An ultrasonic treatment method using the ultrasonic action inducer of the present invention comprises a compound comprising a xanthene dye containing a xanthene ring or a derivative of a xanthene dye (including a dimer), and comprises a threshold of acoustic intensity for generating acoustic cavitation.
  • a step of detecting ultrasonic waves from a target site is a compound comprising a xanthene dye containing a xanthene ring or a derivative of a xanthene dye (including a dimer), and comprises a threshold of acoustic intensity for generating acoustic cavitation.
  • surfactant does not promote acoustic cavitation due to the disadvantageous effect of low interfacial tension during acoustic cavitation. You.
  • surfactants generally form relatively large bubbles, as is prominent in detergents, and it is considered that the large bubbles that have formed adversely affect the formation of acoustic cavitation.
  • the strong surfactant action of surfactants has the effect of destroying cell membranes of living organisms, causing strong biotoxicity. If surfactants have a substance that has the function of promoting the production of acoustic cavitation. Even so, application to living organisms is difficult.
  • Dyes are used to generate short-lived species by light irradiation, and are unlikely to act as scavenging agents for short-lived species.
  • the evaluation of the effect of acoustic cavitation generation was performed using a method that confirmed the generation of subharmonic waves. This method is an acoustic measurement and can directly measure the movement of the bubble itself compared to other methods.
  • ultrasonic waves generate short-lived chemical species such as hydroxyl radicals
  • the subharmonic wave can be measured. The generation must be observed (Ken—ichi Kawabataand Shin—ichiro Umemu ra; The J ourna 1 of Ph ysical Chem istryvol. 100, no. 48, p p. 1 996))).
  • Ultrasonic waves are applied by an ultrasonic probe (details of the configuration will be described later) that measures the generation of acoustic cavitation in a liquid with the configuration shown in Fig. I.
  • the acoustic signal from the sample was measured to determine whether subharmonics were generated.
  • Figure 2 shows the spectrum of a typical acoustic signal when acoustic cavitation occurs.
  • Figure 2 shows a 1 MHz solution of Rose Bengal in a 0.1 mM (millimolar) solution.
  • FIG. 4 is a diagram showing a typical spectrum of an acoustic signal obtained when acoustic cavitation is generated in a liquid by simultaneously irradiating ultrasonic waves of 2 MHz and 2 MHz at an intensity of 5 W / cm 2 for 1 minute.
  • the vertical axis indicates the relative value of the average signal intensity based on 1 ⁇ 10 ′′ 8 (mV) 2 ).
  • Figure 3 shows the intensity of subharmonic waves generated when a solution containing various dyes was irradiated with ultrasonic waves.
  • the intensity of subharmonic waves obtained by irradiating ultrasonic waves to a phosphate buffer solution was measured. Is shown.
  • large subharmonic signals are obtained only in the case of xanthene-based erythrocycin.
  • FIG. 4 is a diagram showing the structure of a compound comprising a xanthene dye or a derivative of a xanthene dye containing a xanthene ring used in a test example of the present invention.
  • FIG. 5 is a diagram showing the structure of a compound comprising a derivative of a xanthene dye or a xanthene dye used in a test example of the present invention.
  • Xanthene dyes are also derivatives of phthalic acid and are also called phthalein dyes. All but phenolphthalene contain a xanthene ring in the molecule. In PH 7.4, the xanthene dye has the structure shown in Fig.
  • Fluorescein F 1 u 0 rescein
  • dichlorofluorescein 2 '7' -D ichlorofluorescein
  • tetrachloro mouth fluorescein 4,5,6,7 — Tetrachlorofluorescein
  • eosin ⁇ osin Y
  • phloxine B P h 1 oxin B
  • rose downy Bengal Ro sebengal
  • the salt of ONa or COONa in which H of OH and COOH is replaced by Na may be used.
  • Figure 6 is a diagram showing the intensity of subharmonic waves generated when a solution containing a xanthene dye or a derivative of a xanthene dye is irradiated with ultrasonic waves.
  • the vertical axis represents the intensity of the subharmonic wave at 1 X 1 CT 7 (mV) 2 Is shown as a relative value based on.
  • Fig. 6 the effect of the xanthene dye containing a halogen atom on the acoustic intensity required for the production of acoustic cavitation was reduced, and the halogen atom was added to the skeleton of the carbon atom of the xanthene dye shown in Fig. 4. It has been confirmed that the compound with the compound has the effect of lowering the sound intensity required for the generation of acoustic cavitation, especially for compounds having two or more halogen atoms in the molecule. .
  • the threshold force of acoustic cavitation in a liquid in which cells such as cancer cells or red blood cells are suspended, ' is lower than the threshold of acoustic cavitation in water, means that proteins on the cell surface may With the core of cavitation It is thought to be due to Based on the belief that it is more effective to lower the threshold of cavitation in body fluids (water) in living organisms, it is more effective to use cells in body fluids as nuclei of cavitation. We searched for compounds that could be present at a higher rate near the surface.
  • Chemical substances in which a functional group capable of binding to a thiol group or amino group of an amino acid is chemically bonded to a xanthene dye have high affinity for cell membranes (Cobb, C and Beth, A; Biochemistry 1. 29, No. 36, pp. 8283-8290 (1990)).
  • a functional group capable of binding to a thiol group or an amino group halogenated acetamide, maleimide, aziridine, isothiocyanate, succinimide, and sulfonyl chloride are known.
  • FIG. 7 is a diagram showing the structure of a compound comprising a xanthene dye or a derivative of a xanthene dye having a functional group capable of chemically bonding to a thiol group or an amino group.
  • the structure of these xanthene dye derivatives is as follows: R, R 2 , R 3 , R 4 , R 5 , R 6) shown in Fig. 4 where R 7 and R 8 are the elements or functional groups shown in Fig. 7. .
  • R 2 shown in FIG. 4 is an iodoacetamido group, an isothiocyanate group, a maleimide group, a derivative of a xanthene dye shown in FIG.
  • acoustic cavitation For acoustic amide (Erythrosin-5-iodoacet amide), erythrosin-5-isothiocyanate, and erythrosin-5-ma1 eimide, acoustic cavitation Lowers the sound intensity required for generation Since interaction with the living body is particularly important for the mechanism, the effect of lowering the threshold of acoustic cavitation was examined using a living body (ddY mouse (os, 5 weeks old)).
  • Each compound shown in Fig. 7 is administered to ddY mice at a dose of 50 mg / Kg body weight, and the ultrasonic device shown in Fig. 8 is used to measure the production of acoustic cavitation in a living body. (Details will be described later) using 0.5 ⁇ ⁇ ⁇ and 1 MHz ultrasonic waves at a sound intensity ratio of 1: 1 to generate subharmonic waves and tissue damage from mouse liver. was observed.
  • FIG. 9 is a diagram showing threshold values of acoustic cavitation in mouse liver when a compound comprising a xanthene dye or a derivative of a xanthene dye having a functional group capable of chemically bonding to a thiol group or an amino group is present.
  • the threshold for acoustic cavitation in the mouse liver was defined as the minimum acoustic intensity that produced both subharmonics and tissue damage.
  • physiological saline was administered to the mice instead of the acoustic cavitation inducer, and the mice were irradiated with ultrasonic waves.
  • halogenated acetamido group, maleimide group, aziridine group, isothiocyanate group, succinimid group, and sulfonyl chloride group which are functional groups capable of binding to a thiol group or an amino group, are: the 4th Regardless of the position of R 2 , R 3 , R 4 , R 5 , R s , R 7 , or R 8 in the carbon atom skeleton of the xanthene dye shown in the figure, a thiol group or is capable of binding with Amino group, R lt R 2, R 3 , R 4, R 5, R 6, R 7, even when in any position of the R a, acoustic needed to generate acoustic Canon bi station It has the effect of reducing strength. Further, a plurality of functional groups capable of bonding to a thiol group or an amino group may be bonded to the carbon atom skeleton of the xanthene dye shown in FIG.
  • Xanthene dyes and derivatives of xanthene dyes generally have high hydrophilicity and, when administered to a living body, flow out of the living body in a relatively short period of time.
  • a protocol that administers to a living body at a relatively high concentration and irradiates the living body with ultrasonic waves in a relatively short time after the administration is effective.
  • xanthene dyes or derivatives of xanthene dyes are considered to be suitable for treatment of calculi, ultrasonic imaging using bubbles, and the like.
  • a method of adding an alkyl group is generally used.
  • Derivatives of xanthene dyes produced by this method have a hydrophobic part and a hydrophilic part in the molecule.
  • Molecules may exist in an aqueous solution or body fluid in the form of micelles, and the physicochemical properties of the molecule in an aqueous solution or body fluid may be a xanthene dye or its derivative. It may be different from the physicochemical properties of the original molecules.
  • Figure 10 shows that two of the molecules consisting of a xanthene dye or a derivative of a xanthene dye are —
  • 2 is a diagram showing the structure of a dimer compound formed by bonding with CH 2 ) n — — (CH 2 ) n — (3 ⁇ n (integer) ⁇ 20), whereby two molecules of a xanthene dye or its A compound having a dimeric structure obtained by cross-linking a derivative is administered to mice, and the generation of subharmonic waves and tissue damage from the liver of the mouse is performed using an ultrasonic device shown in Fig. 8 (details will be described later).
  • acoustic cavitation was measured by the method: Rose Bengal, Rose Bengal Dimer (Structure: Fig. 10 And each compound was administered to d dY mice at a dose of 5 OmgZKg body weight, using an ultrasonic device (see details later) with the configuration shown in FIG. Ultrasonic waves of 5 MHz and 1 MHz were simultaneously irradiated at a sound intensity ratio of 1: 1 to observe the generation of subharmonics and the generation of tissue damage from the mouse liver.
  • Fig. 11 shows the threshold value of acoustic cavitation in the mouse liver in the presence of Rose Bengal dimer, In Fig.
  • the threshold value of acoustic cavitation in the mouse liver is: , Subharmonic and tissue damage Is defined as the minimum sound intensity that produces both In the control experiment shown in Fig. 11, mice were injected with physiological saline and irradiated with ultrasound. Administration of the Rose Bengal dimer and administration of Rose Bengal to mice produced acoustic cavitation at approximately the same sound intensity. From these results, it can be seen that a compound having a dimer structure in which two molecules of a xanthene dye or a derivative thereof are crosslinked by one (CH 2 ) n- (3 ⁇ n (integer) ⁇ 20) has high hydrophobicity.
  • FIG. 1 is a diagram showing a configuration of an ultrasonic apparatus for measuring the generation of acoustic cavitation in a liquid in a test example of the present invention.
  • FIG. 2 shows a typical spectrum of an acoustic signal obtained when acoustic cavitation is generated in a liquid in a test example of the present invention.
  • FIG. 3 shows a test pattern of the present invention.
  • a diagram showing the intensity of subharmonic waves generated when a solution containing various dyes is irradiated with ultrasonic waves
  • FIG. 4 is a diagram showing the structure of a compound comprising a xanthene dye containing a xanthene ring or a derivative of a xanthene dye used in the test example of the present invention
  • FIG. 5 is a diagram showing the xanthene dye used in the test example of the present invention.
  • Figure showing the structure of a compound consisting of a dye or a derivative of a xanthene dye.
  • FIG. 6 is a diagram showing the intensity of subharmonic waves generated when a solution containing a xanthene dye or a derivative of a xanthene dye is irradiated with ultrasonic waves in the test example of the present invention.
  • FIG. 7 is a diagram showing the structure of a compound comprising a xanthene dye or a derivative of a xanthene dye having a functional group capable of chemically bonding to a thiol group or an amino group in a test example of the present invention.
  • FIG. 8 is a diagram showing a configuration of an ultrasonic device for measuring the generation of acoustic cavitation in a living body in a test example of the present invention.
  • FIG. 9 shows the results obtained in the test example of the present invention in the mouse liver when a compound comprising a xanthene dye or a derivative of a xanthene dye having a functional group capable of chemically bonding to a thiol group or an amino group is present.
  • Fig. 11 is a graph showing the threshold value of acoustic cavitation in mouse liver in the presence of Rose Bengal and Rose Bengal dimer in the test example of the present invention.
  • FIG. 12 is a diagram showing a configuration of an ultrasonic apparatus for measuring an antitumor (tumor growth inhibition) effect in a living body in a test example of the present invention.
  • Fig. 13 is a graph showing the dependence of the intensity of the subharmonic wave generated when a solution containing a xanthene dye is irradiated with ultrasonic waves on the acoustic intensity in the test example of the present invention.
  • Fig. 14 is a graph showing the dependence of the amount of active oxygen generated on the sound intensity when a solution containing a xanthene dye was irradiated with ultrasonic waves in the test example of the present invention.
  • FIG. 15 is a graph showing the inhibition rate of tumor growth when mice were administered with Rose Bengal and irradiated with ultrasonic waves in the test example of the present invention.
  • Fig. 16 is a graph showing the calculus breaking ratio when calculus in a solution containing a xanthene dye was irradiated with ultrasonic waves in the test example of the present invention.
  • Fig. 17 shows the results of the modulation produced when a solution containing a derivative of a xanthene dye having a functional group capable of chemically bonding to a thiol group or an amino group was irradiated with ultrasonic waves in the test example of the present invention.
  • Fig. 18 shows the active oxygen content of a solution containing a compound comprising a derivative of a xanthene dye having a functional group capable of chemically bonding to a thiol group or an amino group in a test example of the present invention.
  • Figure showing the dependence of the amount of generated sound on the sound intensity.
  • FIG. 19 is a graph showing the inhibition rate of tumor growth when mice were administered with erythrochloride acetoacetamide and irradiated with ultrasonic waves in the test example of the present invention.
  • FIG. FIG. 4 is a graph showing stone destruction rates when a stone in a solution containing a compound comprising a derivative of a xanthene dye having a functional group capable of chemically bonding to a thiol group or an amino group is irradiated with ultrasonic waves in a test example;
  • Figure 21 shows that in the test example of the present invention, a solution containing a dimer formed by binding two molecules of a xanthene dye or a derivative of a xanthene dye by one (CH 2 ) ⁇ —
  • Fig. 4 shows the dependence of the intensity of the subharmonic generated when sonic waves are irradiated on the acoustic intensity.
  • FIG. 22 shows a solution containing a dimer formed by bonding two molecules of a xanthene dye or a derivative of a xanthene dye with — (CH 2 ) n — in the test example of the present invention.
  • FIG. 23 shows the structure of a dimer formed by bonding two molecules of a xanthene dye or a derivative of a xanthene dye with — (CH 2 ) n — in a test example of the present invention.
  • Fig. 24 shows the results obtained when two molecules of a xanthene dye or a derivative of a xanthene dye are linked by — (CH 2 ) n — in a test example of the present invention.
  • acoustic cavitation in mouse liver Diagram showing the threshold of
  • FIG. 25 is a graph showing the inhibition rate of tumor growth when mice were administered with Rose Bengal dimer and Eris mouth simple acetate amide dimer in a test example of the present invention and irradiated with ultrasonic waves. is there.
  • the relative value is set to 1.
  • FIG. 3 is a diagram illustrating a configuration of an ultrasonic device that measures the generation of acoustic cavitation.
  • the waveform generator 14 synthesizes a sine wave having a frequency of 1 MHz and a sine wave having a frequency of 2 MHz, amplifies the resulting signal with an amplifier 13, and inputs the amplified signal to a planar ultrasonic transducer 9 held by a fixture 10. Ultrasonic waves at frequencies of 1 MHz and 2 MHz are simultaneously radiated from the ultrasonic transducer 9 for 1 to 2 minutes. During the ultrasonic irradiation, the sound pinion signal from the sample solution 4 is held by the holder 8. Underwater microphone 7 Measure more.
  • the acoustic signal measured by the underwater microphone 7 is amplified by the amplifier 11 and then input to the spectrum analyzer 12 to extract the signal component of 500 MHz, which is a subharmonic of 1 MHz, every second. From 15, the time average of the square of the subharmonic component is calculated. The time average of the square of the subharmonic component was defined as the subharmonic intensity, which was used as an index of the magnitude of acoustic cavitation generation.
  • FIG. 3 is a diagram illustrating a configuration of an ultrasonic device that measures the generation of acoustic cavitation.
  • the ultrasound effect inducer was administered at a dose of 5 mg / Kg body weight (Test Example 7) or a dose of 5 OmgZKg body weight (Test Example 13).
  • the mouse 24 After intravenous injection, with the liver 25 exposed outside the body, the mouse 24 was fixed in a water tank 2 filled with degassed water 1, and focused ultrasound at frequencies of 0.5 and 1 MHz was applied at an acoustic intensity ratio. The liver 25 was irradiated at the same time so that the ratio became 1: 1.
  • the converging ultrasonic transducer 26 is composed of piezoelectric elements 28-1, 28-2, ..., 28-N and 0.5MHz ultrasonic waves arranged on a ring for irradiating a 1MHz ultrasonic wave. It consists of piezoelectric elements 29-1, 29-2, ..., 29-N arranged on the irradiation ring.
  • the anesthetized mouse 24 fixed to the fixture 23 is placed in the water tank 2 filled with degassed water 1, and the liver 25 exposed outside the body is fixed at the focal point 27 of the focused ultrasonic transducer 26.
  • Move tool 23 After intravenous injection of an ultrasonic action inducer, ultrasonic waves were conveyed by a convergent ultrasonic transducer 26 for 1 hour. Irradiate for 80 seconds, and visually check for damage to liver 25 during the irradiation time.
  • the acoustic signal obtained from the liver 25 during ultrasonic irradiation is measured with a submerged microphone 31 to check for the presence of the 250 MHz subharmonic component of 0.5 MHz.
  • the minimum acoustic intensity at which the damage and subharmonic waves of the liver 25 were observed by the irradiation of the ultrasonic wave was set as the acoustic cavitation threshold, and it was determined that the acoustic cavitation was generated and that the biological effect was caused by the action of the acoustic cavitation.
  • physiological saline was injected intravenously instead of the ultrasonic wave inducer, and irradiated with ultrasonic waves.
  • the focal point 27 is confirmed using an imaging ultrasonic probe 30 composed of multiple transducers.
  • 32 is a processing circuit for controlling the transmission and reception of ultrasonic waves by the imaging ultrasonic probe 30 and obtaining an image
  • 34 is a transmission waveform generation circuit for driving the piezoelectric element of the converging ultrasonic transducer
  • 33 is an amplifier for amplifying the transmission waveform.
  • Width circuit, 35 is an amplification circuit that amplifies the reception signal of the underwater microphone 31,
  • Reference numeral 36 denotes a reception waveform processing circuit for calculating a time average of the square of the subharmonic component.
  • Evaluation experiment C “Measurement of effects that promote sonochemical reactions"
  • the effect of the ultrasonic action-inducing (attracting) agent of the present invention to promote the sonochemical reaction was determined by measuring the amount of active oxygen produced, which is the source of the antitumor effect by ultrasonic chemical action. investigated.
  • the amount of generated active oxygen was measured by the oxidation reaction of iodine ions generated by the active oxygen.
  • the progress of the reaction was investigated by spectroscopically measuring the concentration of triiodide ion, an oxidation product of iodine ion.
  • Ultrasonic action inducing agent and phosphoric acid buffer solution containing iodide force Riumu each at a concentration of 1 X 10- 4 Micromax and 0. 1 ⁇ ( ⁇ 7.
  • FIG. 12 shows the results of a test using the ultrasonic action-inducing (attracting) agent of the present invention in the following test examples.
  • FIG. 3 is a diagram showing a configuration of an ultrasonic apparatus for measuring an antitumor (tumor growth inhibition) effect in the inside.
  • the configuration of the ultrasonic device shown in FIG. 12 is the same as the configuration of the ultrasonic device shown in FIG.
  • the measurement of the antitumor effect (tumor growth inhibition test) is performed as follows.
  • mice Seven-week-old male BAL BZc mice (3 mice per group) were transplanted with C 0 10 n 26 cells subcutaneously in the abdomen, and then administered an ultrasound inducer when the tumor diameter reached approximately 1 cm. It was injected intravenously to give an amount of 5 OmgZkg body weight.
  • the anesthetized mouse 24 fixed to the fixture 23 is placed in the water tank 2 filled with deaerated water 1, and the subcutaneously implanted tumor of about 1 cm in diameter comes to the focal point 27 of the converging ultrasonic transducer 26. Move the fixture 23. After administration by intravenous injection of ultrasonic action inducing agents, converged by the ultrasound transducer 26, in 0.
  • Tumor growth inhibition rate (%) ((mean tumor weight of control group-mean tumor weight of test group) mean tumor weight of control group) X 100 (1) 0 n26 cells were implanted, and then ultrasound was administered without administration of ultrasound, and mice were implanted with C.sub.10n26 cells and then were administered without administration of ultrasound. It consists of a group that performs sound wave irradiation. W
  • the position of the underwater microphone 31 and the position of the imaging ultrasonic probe 30 may be interchanged.
  • a water jacket may be placed between the front surface of the convergent ultrasonic transducer 26 and the affected area instead of using the water tank 2.
  • Figure 13 shows the dependence of the intensity of the subharmonic generated when a solution containing a xanthene dye is irradiated with ultrasonic waves on the acoustic intensity.
  • Figure 13 shows an example of the test results in accordance with Evaluation Experiment A.
  • an ultrasonic wave inducer such as Phloxine B, Rose Bengal or Erythritis
  • the acoustic intensity is about 2 WZ cm 2.
  • acoustic cavitation occurs, and as the acoustic intensity increases, the cavitation intensity also increases.
  • Test Example 2 "Confirmation test of the effect of xanthene dye on accelerating sonochemical reaction"
  • FIG. 14 shows the dependence of the amount of active oxygen generated on the sound intensity when a solution containing a xanthene dye is irradiated with ultrasonic waves.
  • Fig. 14 shows an example of the test results according to the evaluation experiment C.
  • an ultrasonic action inducer such as Phloxine B, Rose Bengal or Erythritis
  • the sound intensity is about 2 cm 2 or more.
  • active oxygen is generated with increasing acoustic intensity.
  • no active oxygen was generated even at an acoustic intensity of 1 O WZ cm 2 , indicating that the ultrasonic action inducer accelerated the sonochemical reaction in this test example. is there.
  • active oxygen has a bactericidal action as well as an antitumor action, it is clear that the ultrasonic action inducer of the present invention is effective for sterilization by ultrasound.
  • Test example 3 "Confirmation test of rose bengal's antitumor effect (tumor growth inhibition rate)"
  • Fig. 15 shows the tumor growth inhibition rate when rose bengal was administered to mice and irradiated with ultrasound.
  • Figure 15 shows an example of the test results according to evaluation experiment D, showing the results for the xanthene dye rose bengal.
  • the rate of inhibition of tumor growth (inhibition rate) in the case of ultrasonic irradiation was 14.7% in the control experiment, while that in the case of using Rose Bengal was compared. In this case, it was 57.7%, and the antitumor pain effect was about 4 times higher.
  • the antitumor effect of this test example is obtained by the effect of lowering the threshold of the acoustic cavitation and the effect of accelerating the sonochemical reaction of the ultrasonic action inducer of the present invention.
  • xanthene dyes other than Rose Bengal, phloxin B, erythrin syn, tetracro mouth fluorescein, etc. in which halogen is bonded to multiple conjugated carbon atoms, have the same antitumor properties as Rose Bengal. (4) It is expected that an effect can be obtained.
  • phloxine B and erythrocystin show the same effect as Rose Pengal in lowering the acoustic cavitation threshold and producing active oxygen.
  • FIG. 16 shows the stone destruction rate when stones in a solution containing xanthene dye are irradiated with ultrasonic waves.
  • Fig. 16 shows an example of test results according to evaluation experiment E.
  • the phloxin B, rose bengal and erythro-orcin-induced sonication inducers (Macao 1 ⁇ 10 " 4 ) were compared with the control experiment by 2.4 and 2. It showed a stone destruction rate of 2 to 1.9 times, the highest when using Phloxine B, and all of the ultrasonic action inducers were effective in promoting stone destruction.
  • Test Example 5 “Confirmation test of the effect of a compound consisting of a derivative of a xanthene dye having a functional group capable of chemically bonding to a thiol group or amino group to reduce the ⁇ value of sound cavitation in a liquid”
  • FIG. 17 shows the dependence of the intensity of the subharmonic wave generated when a solution containing a compound consisting of a derivative of a xanthene dye having a functional group capable of chemically bonding to a thiol or amino group is irradiated with ultrasonic waves on the acoustic intensity.
  • FIG. In the first 7 figure shows an example of a test result in accordance with the evaluation experiments A, if containing ultrasonic action inducing agent such as Ellis port Shin Yodoase Bok Ami de is acoustic intensity of about 2 W / cm 2 or more Acoustic cavitation has occurred.
  • the control experiment even if the sound intensity was 10 WZ cm 2 , gagged cavitation was generated.
  • Test Example 6 “Confirmation test of the effect of a compound consisting of a derivative of a xanthene dye having a functional group capable of chemically bonding to a thiol group or an amino group to accelerate the sonochemical reaction”
  • FIG. 18 shows the dependence of the amount of active oxygen generated on sound intensity when a solution containing a compound consisting of a derivative of a xanthene dye having a functional group capable of chemically bonding to a thiol group or an amino group is irradiated with ultrasonic waves.
  • FIG. The first 8 figure shows an example of a test result in accordance with the evaluation experiment C, and may include an ultrasound action inducing agent such as Ellis port Shinyo one Doasetoami de is active in acoustic intensity of about 2 W / cm 2 or more Oxygen is being produced.
  • test Example 7 “Confirmation test of the effect of a compound consisting of a xanthene dye or a derivative of a xanthene dye having a functional group capable of chemically bonding to a thiol group or an amino group to lower the threshold of acoustic cavitation in a living body”
  • FIG. 9 is a diagram showing threshold values of acoustic cavitation in mouse liver when a compound comprising a xanthene dye or a derivative of a xanthene dye having a functional group capable of chemically bonding to a thiol group or an amino group is present.
  • Fig. 9 shows an example of the test results according to the evaluation experiment B. Eris mouth Sin, Eris mouth Sindoacetamide, Eris mouth Sin isothiosinate, The threshold value of acoustic cavitation was lower in all cases of Ellis mouth cinmaremid than in the case where no ultrasonic action inducer was administered. The acoustic cavitation threshold was reduced to about 2.4, 1/12, 1/8 and 1/3 by each ultrasonic action inducer.
  • Test Example 8 “Confirmation test of antitumor effect (tumor growth inhibition rate) of erythrocyte syndodoctamide”
  • Fig. 19 is a graph showing the inhibition rate of tumor growth when mice were injected with erythrocyte cindoacetamide and irradiated with ultrasound.
  • Fig. 19 shows an example of the test results obtained in accordance with Evaluation Experiment D, and shows the results for the xanthene dye Eris Mouth Sidodoacetamide.
  • the rate of inhibition of tumor growth (suppression rate) in the case of ultrasonic irradiation was 14.7% in the control experiment, whereas the rate of inhibition in the control experiment was 44.7% when erythrocyte cinnacetamide was used. At 9.7%, an anti-tumor effect of about 3.4 times was obtained.
  • the antitumor effect of this test example is obtained by the effect of the sonication inducer on lowering the threshold of the sound tone and the effect of promoting the sonochemical reaction. It is expected that xanthene dyes other than erythrido-syndoacetamide having an affinity for thiol group or amino group will have the same antitumor effect as erythrocyte-scinodacetamide. Mouth synthiothiocyanate and erythrosine maleimide showed almost the same effects as elimination cinnamate acetoamide in lowering the acoustic cavitation threshold and producing active oxygen ( Test Example 9: “thiol group or amino acid”). Confirmation of the effect of a compound consisting of a derivative of a xanthene dye having a functional group capable of chemically bonding with a group to accelerate stone destruction ”
  • Fig. 20 shows an example of the application of ultrasonic waves to a calculus in a solution containing a compound consisting of a derivative of a xanthene dye having a functional group capable of chemically bonding to a thiol group or an amino group. It is a figure which shows the calculus destruction rate at the time of irradiating.
  • Fig. 20 shows an example of test results according to evaluation experiment E, in which xylose dye acetamido, ellis cinthiothiothiocyanate, and ellis cinmareimide were selected as xanthene dye derivatives.
  • the stone destruction rate was 1.9 times higher, the highest when using Ellis mouth cinnacetacetamide, and all ultrasonic action inducers were effective in promoting stone destruction.
  • Test Example 10 “Test for confirming the effect of erythricular cinnamate acetoamide generating bubbles for ultrasound imaging”
  • Test Example 11 “Confirmation of the effect of dimer and its derivative formed by binding two molecules of xanthene dye by — (CH 2 ) n — to lower the threshold of acoustic cavitation in liquid test”
  • Fig. 21 shows the components generated when a solution containing a dimer formed by combining two molecules of a xanthene dye or a derivative of a xanthene dye with one (CH 2 ) n — is irradiated with ultrasonic waves.
  • FIG. 6 is a diagram showing the dependence of the harmonic intensity on the acoustic intensity.
  • Figure 23 is a diagram showing the structure of a dimer formed by combining two molecules of a xanthene dye or a derivative of a xanthene dye with one (CH 2 ) n —. shown, shown xanthene dyes or hexa pentene in the dimer of the dye derivative R t, R 2, R 3 , R 4> R s, the R 6, R 7, R 8 .
  • Figure 21 shows an example of the test results according to evaluation experiment C.
  • an ultrasonic wave inducer such as a Rose Bengal dimer
  • the acoustic intensity is about 2 WZ cm 2 or more and the acoustic cavitation is not possible. Has occurred.
  • control of the acoustic intensity in experiments does not occur acoustic Kiyabiteshiyon even 1 OWZ cm 2
  • an ultrasonic action inducing agent in the present test example lowers the acoustic Kiyabiteshi ® emission threshold 1 Z5 below It is clear that there is.
  • Test Example 12 “Confirmation test of the effect of a dimer and its derivative formed by bonding two molecules of a xanthene dye by — (CH 2 ) ⁇ — to accelerate the sonochemical reaction”
  • FIG. 22 shows active oxygen when a solution containing a dimer formed by combining two molecules consisting of a xanthene dye or a derivative of a xanthene dye by one (CH 2 ) n — is irradiated with ultrasonic waves.
  • FIG. 4 is a diagram showing the dependence of the amount of generated sound on the sound intensity.
  • Figure 22 shows an example of the test results according to evaluation experiment C. When an ultrasonic wave inducer such as rose bengal dimer is included, active oxygen is generated at an acoustic intensity of about SWZcm 2 or more. I have. In contrast, in the control experiment, no active oxygen was generated even at an acoustic intensity of 1 OWZcm 2 .
  • FIG. 23 is a diagram showing the structure of a dimer formed by bonding two molecules of a xanthene dye or a derivative of a xanthene dye with — (CH 2 ) n —, as shown in FIG.
  • FIG. 24 xanthene dyes or two molecular consisting derivatives of xanthene dyes one (CH 2) ⁇ - when the dimer is formed by bonding by the presence, in the acoustic Kiyabite in mouse liver It is a figure showing a threshold of one shot.
  • Fig. 24 shows an example of the test results according to the evaluation experiment II. Rosebengal dimer, ellis mouth succinoacetamide dimer, eosin isothiosinate dimer, fluorescein male The threshold of acoustic cavitation was lower in all of the mid dimers than in the case where no ultrasonic action inducer was administered.
  • Test Example 14 “One molecule of xanthene dye is one (CH 2 ). Confirmation test of antitumor effect (tumor growth inhibition rate) of dimer and its derivative formed by binding together
  • Figure 25 shows the tumor growth inhibition rate when mice were administered with Rose Bengal dimer and Elis succinoacetoamide dimer and irradiated with ultrasound.
  • Fig. 25 shows an example of the test results according to Evaluation Experiment D, and shows the results for dioxbengal dimer and erythrox cinnamate acetamide dimer.
  • the inhibition rate of tumor growth with ultrasound irradiation was 10.1% in the control experiment, whereas it was 70.5% when Rose Bengal dimer was used, and In contrast, when Eris mouth succinoacetamide dimer was used, it was 73.2%, and the antitumor effect was about 7 times higher.
  • the antitumor effect of the rose pengal dimer in this test example is about twice that of the antitumor effect of rose bengal monomer in test example 3.
  • the antitumor effect in this test example was determined from the results of Test Examples 11 and 12. It was confirmed that the ultrasonic action inducer of the present invention was obtained by the effect of lowering the threshold value of acoustic cavitation and the effect of promoting the chemical reaction of sound. It should be noted that a dimer of a xanthene dye having a functional group other than an acetoacetamide group capable of binding to a thiol group or an amino group also has an antitumor effect equivalent to that of an erythrocyte sio-doacetamide dimer.
  • the threshold value of sound cavitation can be reduced, and irradiation of ultrasonic waves with low acoustic intensity can benign or malignant tumors and calculi. Treatment can be performed safely.
  • the present invention is summarized as follows.
  • a xanthene dye containing a xanthene ring or It contains a compound consisting of a derivative of a xanthene dye (including a dimer) and is an agent that induces the action of ultrasound that lowers the threshold of sound intensity that produces acoustic cavitation.
  • halogen halogenated Asetoami de group, male imide group , Aziridine, isothiocyanate, succinimid, or sulfonyl chloride.
  • the threshold of acoustic intensity for the generation of acoustic cavitation can be lowered, and the treatment of benign or malignant tumors and calculi can be safely performed by irradiating low-intensity ultrasonic waves.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention concerne des médicaments contenant des composés de colorants à base de xanthène ou de dérivés de tels composés (y compris des dimères) comportant un ou plusieurs noyaux xanthène. Lesdits médicaments induisent une action ultrasonore se traduisant par un abissement du seuil de rigidité acoustique provoquant une cavitation acoustique. Dans ces médicaments, tout groupe R1 à R8 lié à des atomes de carbone du squelette du colorant à base de xanthène, est un groupe fonctionnel susceptible de former une liaison chimique avec un groupe halogéno, thiol ou amino (sélectionné parmi un acétamide halogéné, un maléimide, une aziridine, un isothiocyanate, un succinimide et un chlorure de sulfuryle). Du fait qu'ils sont capables d'abaisser ledit seuil, ces médicaments permettent de traiter en toute sécurité des tumeurs béniges ou malignes ou des calculs au moyen d'une irradiation par des ondes ultrasonores de faible rigidité acoustique.
PCT/JP1997/002285 1996-07-05 1997-07-02 Medicaments induisant une action ultrasonore et appareil d'utilisation de ces medicaments WO1998001131A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP8/176207 1996-07-05
JP17620796 1996-07-05
JP9/31993 1997-02-17
JP3199397 1997-02-17

Publications (1)

Publication Number Publication Date
WO1998001131A1 true WO1998001131A1 (fr) 1998-01-15

Family

ID=26370509

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1997/002285 WO1998001131A1 (fr) 1996-07-05 1997-07-02 Medicaments induisant une action ultrasonore et appareil d'utilisation de ces medicaments

Country Status (1)

Country Link
WO (1) WO1998001131A1 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998052610A1 (fr) * 1997-05-22 1998-11-26 Technion Research And Development Foundation Ltd. Therapie photodynamique et sonodynamique et agents et systeme utilises a cet effet
WO1998052609A1 (fr) * 1997-05-19 1998-11-26 Nycomed Imaging As Therapie sonodynamique mettant en oeuvre un compose sensibilisant ultrasonore
JP2002017742A (ja) * 2000-06-30 2002-01-22 Hitachi Ltd 超音波治療装置
JP2003531834A (ja) * 2000-04-06 2003-10-28 フォトゲン インク 疾病の高エネルギー光線療法治療のための体内薬剤
JP2004503592A (ja) * 2000-07-14 2004-02-05 フォトゲン　インク 疾患の化学療法治療用薬剤
EP1393775A1 (fr) 2002-08-28 2004-03-03 Hitachi, Ltd. Appareil à ultrasons pour utilisation thérapeutique
WO2004052407A1 (fr) * 2002-12-09 2004-06-24 Xantech Pharmaceuticals, Inc. Contraste ultrasonore realise a l'aide de xanthenes halogenes
US7074427B2 (en) 2002-01-30 2006-07-11 Hitachi, Ltd. Medicine, carrier for medicine, method of producing medicine, and method of tumor treatment
WO2007049708A1 (fr) 2005-10-26 2007-05-03 Toto Ltd. Accelerateur de therapie cancereuse ultrasonique et agent cytotoxique
US7824336B2 (en) 2005-05-17 2010-11-02 Hitachi, Ltd. Ultrasonic apparatus for diagnosis and therapy
US9078594B2 (en) 2010-04-09 2015-07-14 Hitachi, Ltd. Ultrasound diagnostic and treatment device
WO2016148215A1 (fr) * 2015-03-17 2016-09-22 国立大学法人東京大学 INHIBITEUR DE Mint 3

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63264064A (ja) * 1987-04-07 1988-10-31 ベベセ 器具殺菌方法及び装置
JPH0629196B2 (ja) * 1987-12-01 1994-04-20 甲子郎 梅村 超音波による腫瘍治療用生理作用増強剤
JPH08176017A (ja) * 1994-08-04 1996-07-09 Touin Gakuen 超音波用造影剤及びその製造方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63264064A (ja) * 1987-04-07 1988-10-31 ベベセ 器具殺菌方法及び装置
JPH0629196B2 (ja) * 1987-12-01 1994-04-20 甲子郎 梅村 超音波による腫瘍治療用生理作用増強剤
JPH08176017A (ja) * 1994-08-04 1996-07-09 Touin Gakuen 超音波用造影剤及びその製造方法

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998052609A1 (fr) * 1997-05-19 1998-11-26 Nycomed Imaging As Therapie sonodynamique mettant en oeuvre un compose sensibilisant ultrasonore
US6498945B1 (en) 1997-05-19 2002-12-24 Amersham Health As Sonodynamic therapy using an ultrasound sensitizer compound
WO1998052610A1 (fr) * 1997-05-22 1998-11-26 Technion Research And Development Foundation Ltd. Therapie photodynamique et sonodynamique et agents et systeme utilises a cet effet
US6986740B2 (en) 1998-11-02 2006-01-17 Xantech Pharmaceuticals, Inc. Ultrasound contrast using halogenated xanthenes
JP2003531834A (ja) * 2000-04-06 2003-10-28 フォトゲン インク 疾病の高エネルギー光線療法治療のための体内薬剤
JP2002017742A (ja) * 2000-06-30 2002-01-22 Hitachi Ltd 超音波治療装置
JP2004503592A (ja) * 2000-07-14 2004-02-05 フォトゲン　インク 疾患の化学療法治療用薬剤
US7074427B2 (en) 2002-01-30 2006-07-11 Hitachi, Ltd. Medicine, carrier for medicine, method of producing medicine, and method of tumor treatment
US7125387B2 (en) 2002-08-28 2006-10-24 Hitachi, Ltd. Ultrasonic apparatus for therapeutical use
EP1393775A1 (fr) 2002-08-28 2004-03-03 Hitachi, Ltd. Appareil à ultrasons pour utilisation thérapeutique
JP2006510677A (ja) * 2002-12-09 2006-03-30 ザンテック ファーマスーティカルズ，インク． ハロゲン化キサンテンを使用する超音波造影
WO2004052407A1 (fr) * 2002-12-09 2004-06-24 Xantech Pharmaceuticals, Inc. Contraste ultrasonore realise a l'aide de xanthenes halogenes
US7824336B2 (en) 2005-05-17 2010-11-02 Hitachi, Ltd. Ultrasonic apparatus for diagnosis and therapy
WO2007049708A1 (fr) 2005-10-26 2007-05-03 Toto Ltd. Accelerateur de therapie cancereuse ultrasonique et agent cytotoxique
US8992958B2 (en) 2005-10-26 2015-03-31 Toto Ltd. Ultrasonic cancer treatment enhancer and cell killer
US9078594B2 (en) 2010-04-09 2015-07-14 Hitachi, Ltd. Ultrasound diagnostic and treatment device
WO2016148215A1 (fr) * 2015-03-17 2016-09-22 国立大学法人東京大学 INHIBITEUR DE Mint 3
JP2016172705A (ja) * 2015-03-17 2016-09-29 国立大学法人 東京大学 Ｍｉｎｔ３阻害剤

Similar Documents

Publication Publication Date Title
Umemura et al. In vitro and in vivo enhancement of sonodynamically active cavitation by second-harmonic superimposition
Umemura et al. Recent advances in sonodynamic approach to cancer therapy
Giesecke et al. Ultrasound-mediated cavitation thresholds of liquid perfluorocarbon droplets in vitro
Rosenthal et al. Sonodynamic therapy––a review of the synergistic effects of drugs and ultrasound
Umemura et al. Sonodynamically induced effect of rose bengal on isolated sarcoma 180 cells
Yumita et al. Sonodynamically induced antitumor effect of a gallium‐porphyrin complex, ATX‐70
Rapoport et al. Cavitation properties of block copolymer stabilized phase-shift nanoemulsions used as drug carriers
US20030147812A1 (en) Device and methods for initiating chemical reactions and for the targeted delivery of drugs or other agents
WO1998001131A1 (fr) Medicaments induisant une action ultrasonore et appareil d'utilisation de ces medicaments
US20040068207A1 (en) Active oxygen generator containing photosensitizer for ultrasonic therapy
US20100178305A1 (en) Ultrasonic nanotherapy of solid tumors with block copolymers stabilized perfluorocarbon nanodroplets
Miller et al. Contrast-agent gas bodies enhance hemolysis induced by lithotripter shock waves and high-intensity focused ultrasound in whole blood
CA2290450A1 (fr) Therapie photodynamique et sonodynamique et agents et systeme utilises a cet effet
Dong et al. Cold plasma gas loaded microbubbles as a novel ultrasound contrast agent
Shanei et al. An overview of therapeutic applications of ultrasound based on synergetic effects with gold nanoparticles and laser excitation
Yumita Membrane lipid peroxidation as a mechanism of sonodynamically induced erythrocyte lysis
JP3816809B2 (ja) 薬剤、薬剤キャリア、薬剤の製造方法及び腫瘍の治療方法
Perng et al. Ultrasound imaging of oxidative stress in vivo with chemically-generated gas microbubbles
Choi et al. Synergistic agents for tumor-specific therapy mediated by focused ultrasound treatment
JP2008100956A (ja) がん治療用組成物
Bader et al. Overview of Therapeutic Ultrasound Applications and Safety Considerations: 2024 Update
KONDO et al. Novel therapeutic applications of ultrasound. Utilization of thermal and cavitational effects
Kawabata et al. 1f-3 site-specific contrast imaging with locally induced microbubbles from liquid precursors
Topaz et al. EPR analysis of radicals generated in ultrasound-assisted lipoplasty simulated environment
CN108721648B (zh) 一种多功能微泡及其制备方法和应用

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CN JP KR US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase